Linked Data API

Show Search Form

Search Results

100816
registered interest false more like this
date less than 2014-10-23more like thismore than 2014-10-23
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Terminal Illnesses more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what guidance his Department has issued to health technology appraisal committees on application of NICE's end of life criteria when appraising treatments for patients with terminal illness. more like this
tabling member constituency Redcar more like this
tabling member printed
Ian Swales more like this
uin 211809 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-28more like thismore than 2014-10-28
answer text <p>The Department has not issued any such guidance. The National Institute for Health and Care Excellence is an independent body and is responsible for the development of its methods and processes.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-10-28T14:56:20.6436753Zmore like thismore than 2014-10-28T14:56:20.6436753Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4045
label Biography information for Ian Swales more like this
100817
registered interest false more like this
date less than 2014-10-23more like thismore than 2014-10-23
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Terminal Illnesses more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what rationale lies behind NICE's advice that end-of-life criteria should only apply to medicines that extend life by at least three months. more like this
tabling member constituency Redcar more like this
tabling member printed
Ian Swales more like this
uin 211807 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-28more like thismore than 2014-10-28
answer text <p>In January 2009, the National Institute for Health and Care Excellence (NICE) issued supplementary advice to its appraisal committees on appraising treatments which may be life-extending for patients, with short life expectancy, and which are licensed for indications affecting small numbers of patients with incurable illnesses.</p><p> </p><p> </p><p> </p><p>This sets out the following three criteria that must all be satisfied for this supplementary advice to be applied:</p><p> </p><p>- the treatment is indicated for patients with a short life expectancy, normally less than 24 months;</p><p> </p><p>- there is sufficient evidence to indicate that the treatment offers an extension to life, normally of at least an additional three months, compared to current NHS treatment; and</p><p> </p><p>- the treatment is licensed or otherwise indicated, for small patient populations.</p><p> </p><p> </p><p> </p><p>These criteria were developed following public consultation and set out the circumstances when NICE considers it is appropriate for its appraisal committees to apply greater flexibility in their appraisal of these treatments.</p><p> </p><p> </p><p> </p><p>The advice has now been incorporated chapter 6 of <em>Guide to the methods of technology appraisal 2013 </em>which can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making" target="_blank">www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making</a></p><p> </p><p> </p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-10-28T14:27:08.2752956Zmore like thismore than 2014-10-28T14:27:08.2752956Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4045
label Biography information for Ian Swales more like this
100402
registered interest false more like this
date less than 2014-10-22more like thismore than 2014-10-22
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Paralysis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps he has taken to support University College London in its work to enable people who have been paralysed to regain the ability to walk. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon more like this
uin 211576 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-27more like thismore than 2014-10-27
answer text <p>The Department’s National Institute for Health Research (NIHR) funds 11 biomedical research centres that conduct translational research to transform scientific breakthroughs into benefits for patients. These centres are formed through partnerships between England’s leading National Health Service organisations and universities.</p><p> </p><p> </p><p> </p><p>The NIHR is investing £110 million over five years (2012-17) in the NIHR biomedical research centre at University College London Hospitals NHS Foundation Trust and University College London. The centre is supporting research on the use of cells from the lining of the nose to repair damaged nerves in the spinal cord.</p><p> </p><p><strong> </strong></p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-10-27T16:53:22.0851128Zmore like thismore than 2014-10-27T16:53:22.0851128Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4131
label Biography information for Jim Shannon more like this
100411
registered interest false more like this
date less than 2014-10-22more like thismore than 2014-10-22
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Cystic Fibrosis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps the Government is taking to support research into new treatments for people with cystic fibrosis. more like this
tabling member constituency Barnsley Central more like this
tabling member printed
Dan Jarvis more like this
uin 211584 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-27more like thismore than 2014-10-27
answer text <p>The National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre manages the Efficacy and Mechanism Evaluation programme. With funding from the Medical Research Council, this programme is currently supporting a £3.3 million trial of repeated application of gene therapy in patients with cystic fibrosis. The report of this trial is expected to be published in August 2015.</p><p> </p><p><strong> </strong></p><p> </p><p>A range of commercial and researcher-led cystic fibrosis treatment trials and studies are hosted by NIHR research infrastructure including the NIHR Clinical Research Network, NIHR biomedical research centres and units, and NIHR clinical research facilities for experimental medicine.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-10-27T16:52:12.8962611Zmore like thismore than 2014-10-27T16:52:12.8962611Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4243
label Biography information for Dan Jarvis more like this
100186
registered interest false more like this
date less than 2014-10-21more like thismore than 2014-10-21
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Patients: Safety more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, whether missed or inadequate hydrocortisone administration is included in the NHS list of Never Events. more like this
tabling member constituency Oxford East more like this
tabling member printed
Mr Andrew Smith more like this
uin 211233 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-28more like thismore than 2014-10-28
answer text <p>Missed or inadequate hydrocortisone administration is not currently included in the list of ‘never events’.</p><p> </p><p> </p><p> </p><p>We can confirm that the current list of Never Events is under review and there is a consultation underway which opened online on the 6 October 2014 and closes on 31 October 2014.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-10-28T15:28:25.797Zmore like thismore than 2014-10-28T15:28:25.797Z
question first ministerially corrected
less than 2014-10-28T16:30:53.2329022Zmore like thismore than 2014-10-28T16:30:53.2329022Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
24770
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
answering member 3918
tabling member
95
label Biography information for Mr Andrew Smith more like this
99859
registered interest false more like this
date less than 2014-10-20more like thismore than 2014-10-20
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Prescription Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, if his Department will commission a review of the innovation, evaluation and adoption of new medicines in the NHS; and if he will make a statement. more like this
tabling member constituency Scunthorpe more like this
tabling member printed
Nic Dakin more like this
uin 211101 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-23more like thismore than 2014-10-23
answer text <p>We are committed to ensuring National Health Service patients have access to effective medicines on terms that represent value to the NHS and taxpayers and that patients, are supported to get the best outcomes from their medicines.</p><p> </p><p> </p><p> </p><p>The Department, in collaboration with NHS England, has recently commissioned an independent evaluation of Innovation Health and Wealth. Jointly led by the University of Manchester and RAND Europe, The first initial phase is now underway, the study is expected to take three years to complete.</p><p> </p><p><em> </em></p><p> </p><p>In addition, NHS England, with the Health and Social Care Information Centre publishes an innovation scorecard which represents the rate of uptake and utility of medicines in both primary and secondary care, on a regular basis. This publication sets out levels of uptake and utility for National Institute for Health and Care Excellence appraised medicines and technologies, and evidence suggests that steady growth is being achieved and the most recent information is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/searchcatalogue?productid=15598&amp;q=innovation+scorecard&amp;sort=Relevance&amp;size=10&amp;page=1#top" target="_blank">www.hscic.gov.uk/searchcatalogue?productid=15598&amp;q=innovation+scorecard&amp;sort=Relevance&amp;size=10&amp;page=1#top</a></p><p> </p><p><strong> </strong></p><p> </p><p>Earlier this year, NHS England also undertook an extensive consultation to ‘refresh’ the Innovation Health and Wealth policy framework and we understand that recommendations from this will be included in NHS England's five year Forward Look.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-10-23T16:35:13.9262134Zmore like thismore than 2014-10-23T16:35:13.9262134Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4056
label Biography information for Nic Dakin more like this
99878
registered interest false more like this
date less than 2014-10-20more like thismore than 2014-10-20
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Hepatitis: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much his Department spent on medicines for hepatitis C treatment in each of the last three financial years. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Luciana Berger more like this
uin 211146 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-23more like thismore than 2014-10-23
answer text <p>Information on spend by the National Health Service in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p> </p><p>Medicines for the treatment of hepatitis C have been defined as all medicines contained within British National Formulary section 5.3.3.4 - chronic hepatitis C. In addition, peginterferon alfa, ribavirin and interferon alfa have also been included as they have been recommended in National Institute for Health and Care excellence technology appraisals for use in treating hepatitis C.</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition, it may not be possible to separate the different conditions for which a drug may have been prescribed and therefore figures may include costs from prescriptions of these drugs other than for hepatitis C.</p><p> </p><p><strong> </strong></p><p> </p><p>This is the cost of the medicines at NHS list price and not necessarily the price paid. It does not take account of discounts, dispensing costs, fees or prescription charges income.</p><p> </p><p> </p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Financial Year</p></td><td><p>Cost (£000)</p></td></tr><tr><td><p>2011-12</p></td><td><p>34,198.9</p></td></tr><tr><td><p>2012-13</p></td><td><p>52,709.2</p></td></tr><tr><td><p>2013-14</p></td><td><p>72,122.0</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-10-23T16:40:20.5892873Zmore like thismore than 2014-10-23T16:40:20.5892873Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4036
label Biography information for Luciana Berger more like this
93839
registered interest false more like this
date less than 2014-10-16more like thismore than 2014-10-16
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Mental Health Services more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what National Institute for Health and Care Excellence-approved interventions are available through the NHS for the treatment of mental health conditions. more like this
tabling member constituency East Worthing and Shoreham more like this
tabling member printed
Tim Loughton more like this
uin 210896 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-21more like thismore than 2014-10-21
answer text <p>The National Institute for Health and Care Excellence (NICE) has published clinical guidelines on a range of mental health topics, such as depression, anxiety and schizophrenia. Clinical guidelines provide guidance on the treatment of patients across the care pathway and each guideline recommends a number of treatments.<br> <br> Additionally, the following technologies for the treatment of mental health and behavioural conditions are recommended by NICE technology appraisal guidance:</p><p> </p><table><tbody><tr><td><p>Appraisal Number</p></td><td><p>Year</p></td><td><p>Technology</p></td><td><p>Condition</p></td><td><p>Categorisation</p></td></tr><tr><td><p>TA59</p></td><td><p>2003</p></td><td><p>Electroconvulsive therapy</p></td><td><p>Catatonia/ prolonged or severe manic episode</p></td><td><p>Optimised<sup>1</sup></p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Atomoxetine</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Dexamfetamine</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Methylphenidate</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA213</p></td><td><p>2011</p></td><td><p>Aripiprazole</p></td><td><p>Schizophrenia in people aged 15-17 years</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Donepezil</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Galantamine</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Rivastigmine</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Memantine</p></td><td><p>Alzheimer's disease (moderate)</p></td><td><p>Optimised</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Memantine</p></td><td><p>Alzheimer's disease (severe)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA292</p></td><td><p>2013</p></td><td><p>Aripiprazole</p></td><td><p>Moderate to severe manic episodes in adolescents with bipolar disorder</p></td><td><p>Recommended</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><em>Source</em>: National Institute for Health and Care Excellence</p><p> </p><p> </p><p> </p><p><sup>1 </sup>The drug or technology is recommended for a smaller subset of patients than originally stated by the marketing authorisation.</p><p> </p><p> </p><p> </p><p>Patients have the right to drugs and treatments that have been recommended by NICE technology appraisal guidance for use in the National Health Service, where their doctor believes they are clinically appropriate.</p><p> </p><p> </p><p> </p><p>Details of all NICE’s guidance on mental health and behavioural conditions can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions" target="_blank">www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions</a></p><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-10-21T15:12:00.8391961Zmore like thismore than 2014-10-21T15:12:00.8391961Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
114
label Biography information for Tim Loughton more like this
100022
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Patient Choice Schemes more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps he is taking to promote patient choice. more like this
tabling member constituency Stroud more like this
tabling member printed
Neil Carmichael more like this
uin 905559 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-21more like thismore than 2014-10-21
answer text <p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.</p><p> </p><p> </p><p> </p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-10-21T16:00:56.1397924Zmore like thismore than 2014-10-21T16:00:56.1397924Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4104
label Biography information for Neil Carmichael more like this
93556
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Pharmaceutical Price Regulation Scheme more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what discussions (a) he or (b) officials in his Department have had on reinvesting the industry rebate payments under the current Pharmaceutical Price Regulation Scheme into (i) healthcare services and (ii) medicines expenditure. more like this
tabling member constituency Cambridge more like this
tabling member printed
Dr Julian Huppert more like this
uin 210807 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-22more like thismore than 2014-10-22
answer text <p>The Pharmaceutical Price Regulation Scheme (PPRS) as agreed with the Association of the British Pharmaceutical Industry (ABPI) does not cover the onward financial flows of payments to the National Health Service which are subject to the Government accounting and budgeting rules in the normal way. In particular there was no agreement to hypothecate PPRS payments. The Department has subsequently had a number of discussions with the ABPI and NHS England about the onward financial flows.</p><p> </p><p> </p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the mandate and as such were included within commissioner allocations. The same is expected to apply in 2015-16. This means that the effect of the deal is felt across the NHS through the general funding allocations to clinical commissioning groups.</p><p> </p><p> </p><p> </p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the ABPI are discussing how best to improve access to and optimise patient outcomes from these medicines.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-10-22T15:38:43.80669Zmore like thismore than 2014-10-22T15:38:43.80669Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
3931
label Biography information for Dr Julian Huppert more like this